Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Effective Intralesional Melanoma Therapy May Involve Systemic Effects.

2.

Detecting pancreatic cancer through changes in body composition and metabolism

3.

Virtual Reality Travel Reduces Cancer Pain.

4.

EMA Recommends Generic in Advanced/Metastatic Breast Cancer

5.

Immune cell homing hydrogel-based platform captures dendritic cells to process mRNA from cancer vaccines


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot